Fig. 4From: Influence of continuous erythropoietin receptor activator (CERA) administration intervals on erythropoietic effect in hemodialysis patientsReticulocyte counts and hemoglobin levels when 100 μg of CERA per 4 weeks was administered by Q2W, Q4W, and Q1WBack to article page